Novartis AG reported impairment charges for the fourth quarter of 2020. For the quarter, the company reported net impairment charges for property, plant and equipment from continuing operations amounted to USD 37 million (2019: USD 42 million) of which USD 33 million (2019: USD 15 million) in the Innovative Medicines Division and USD 4 million (2019: USD 27 million) in the Sandoz Division.